Takeda Pharmaceutical Company Limited (TKPHF)
| Market Cap | 52.53B +11.3% |
| Revenue (ttm) | 28.34B -1.7% |
| Net Income | -958.40M |
| EPS | -0.61 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 1.30 (3.75%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 96,405 |
| Open | 34.70 |
| Previous Close | n/a |
| Day's Range | 34.70 - 34.70 |
| 52-Week Range | 26.33 - 39.20 |
| Beta | 0.09 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About TKPHF
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enan... [Read more]
News
Takeda Pharmaceutical Co Ltd (TAK) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 77/100
Takeda Pharmaceutical Co Ltd (TAK) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 77/100
Insilico Medicine Announces Strategic AI Drug Discovery Collaboration With Takeda
(RTTNews) - Insilico Medicine (3696.HK), a clinical-stage company specializing in generative AI for drug discovery, has entered into a strategic collaboration with Takeda Pharmaceutical Company Ltd. (...
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader...
Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million
Takeda is set to pay InSilico to use its proprietary Pharma. AI platform to advance drug candidates across several therapeutic areas, according to people familiar with the matter.
Takeda Appoints Julie Kim President & CEO Following 18-Month Transition As Weber Retires
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK) announced that the Board of Directors has officially appointed Julie Kim as the company's Representative Director, President and Chief Executive...
Takeda CEO Christophe Weber retires, Julie Kim succeeds
Takeda (TAK) announced that Julie Kim was officially appointed Takeda’s representative director, president and CEO. During the annual general meeting of shareholders, which took place in Osaka, Japan,...
Takeda Names Julie Kim CEO As Christophe Weber Retires
(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK, 4502.T) announced on Wednesday that it has appointed Julie Kim as President and CEO, completing an 18-month leadership transition.
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the final step of its 18-month CEO transition, Takeda (TOKYO:4502/NYSE:TAK) today announced that Julie Kim was officially appointed Takeda's Repres...
Takeda Canada reports ‘positive’ results from Phase 3 study of zasocitinib
Takeda (TAK) Canada is pleased to announce positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib, an investigational, next-generation, highly sele...
Takeda Canada Announces Positive Topline Results For Phase 3 LATITUDE Atlas Study For Psoriasis
(RTTNews) - Takeda Canada, Inc., a Canadian subsidiary of Japan's Takeda Pharmaceutical Co. Ltd. (TAK), announced Tuesday positive topline results for the Phase 3, randomized, multicenter, double-blin...
Takeda Releases New Positive Phase 3 FirstLight And RadiantLight Data For Oveporexton In Narcolepsy
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK), a pharmaceutical company, on Monday reported new data from the Phase 3 FirstLight and RadiantLight trials for Oveporexton in treating Type 1 Na...
Takeda presents additional results from oveporexton studies at SLEEP 2026
Takeda (TAK) presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton, an oral orexin receptor 2-selective agonist, improved daily functioning as well as cognitive and ...
New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin re...
Takeda announces results for Phase 3 study of TAK-279
Takeda (TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib, TAK-279, an investigational, next-generation, highly selective and p...
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Japan's Takeda Pharmaceutical said on Thursday its experimental once-daily psoriasis pill, developed with the help of AI, outperformed Bristol Myers Squibb's approved drug Sotyktu in a late-stage hea...
Takeda's Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-...
FDA Accepts Takeda's SBLA For ENTYVIO IV In Pediatric UC And Crohn's Disease; PDUFA Set In Q1,2027
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application or sBLA for intravenous ENTY...
FDA accepts Takeda’s application for intravenous Entyvio
Takeda (TAK) announced the U.S. Food and Drug Administration has accepted for review its supplemental Biologics License Application for intravenous ENTYVIO for the treatment of moderately to severely ...
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Appl...
Takeda Pharmaceutical Company Transcript: Jefferies Global Healthcare Conference 2026
Leadership transition is underway with Julie Kim as CEO, supported by a refreshed executive team and board. Three major product launches are expected to drive growth, while a transformation plan aims for significant cost savings and improved margins. ENTYVIO and plasma-derived therapies remain key revenue drivers amid evolving market dynamics.
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
BOSTON--(BUSINESS WIRE)---- $TAK #antitrust--A class-action lawsuit regarding Amitiza ended today when a jury found Takeda Pharmaceuticals liable for $474 million, according to Hagens Berman.
Jury finds Takeda caused about $885M in damages over generic delay, Reuters says
A U.S. jury on Monday determined that Takeda (TAK) Pharmaceutical caused pharmacies, insurers, retailers, and others to sustain roughly $885M in damages by postponing the release of a generic version…
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
A U.S. jury on Monday found that Takeda Pharmaceutical caused pharmacies, insurers, retailers and others to sustain about $885 million in damages delaying the release of a generic version o...
Takeda told to pay hundreds of millions for generic drug delay, Bloomberg says
A federal jury in the U.S. District Court for the District of Massachusetts found Takeda (TAK) Pharmaceuticals liable for violating antitrust law by delaying the generic version of its branded…
Takeda ordered by pay hundreds of millions in antitrust case, Bloomberg says
14:25 EDT Takeda (TAK) ordered by pay hundreds of millions in antitrust case, Bloomberg says